164 related articles for article (PubMed ID: 27535746)
1. Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab.
Nelson SJ; Li Y; Lupo JM; Olson M; Crane JC; Molinaro A; Roy R; Clarke J; Butowski N; Prados M; Cha S; Chang SM
J Neurooncol; 2016 Oct; 130(1):171-179. PubMed ID: 27535746
[TBL] [Abstract][Full Text] [Related]
2. Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.
Nelson SJ; Kadambi AK; Park I; Li Y; Crane J; Olson M; Molinaro A; Roy R; Butowski N; Cha S; Chang S
Neuro Oncol; 2017 Mar; 19(3):430-439. PubMed ID: 27576874
[TBL] [Abstract][Full Text] [Related]
3. 3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.
Muruganandham M; Clerkin PP; Smith BJ; Anderson CM; Morris A; Capizzano AA; Magnotta V; McGuire SM; Smith MC; Bayouth JE; Buatti JM
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):181-9. PubMed ID: 24986746
[TBL] [Abstract][Full Text] [Related]
4. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
Wen Q; Jalilian L; Lupo JM; Molinaro AM; Chang SM; Clarke J; Prados M; Nelson SJ
J Neurooncol; 2015 Jan; 121(2):331-9. PubMed ID: 25351579
[TBL] [Abstract][Full Text] [Related]
5. Early Metabolic Changes in 1H-MRSI Predictive for Survival in Patients With Newly Diagnosed High-grade Glioma.
Wang MH; Roa W; Wachowicz K; Yahya A; Murtha A; Amanie J; Chainey J; Quon H; Ghosh S; Patel S
Anticancer Res; 2022 May; 42(5):2665-2673. PubMed ID: 35489774
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
Ratai EM; Zhang Z; Snyder BS; Boxerman JL; Safriel Y; McKinstry RC; Bokstein F; Gilbert MR; Sorensen AG; Barboriak DP
Neuro Oncol; 2013 Jul; 15(7):936-44. PubMed ID: 23645534
[TBL] [Abstract][Full Text] [Related]
7. Volumetric spectroscopic imaging of glioblastoma multiforme radiation treatment volumes.
Parra NA; Maudsley AA; Gupta RK; Ishkanian F; Huang K; Walker GR; Padgett K; Roy B; Panoff J; Markoe A; Stoyanova R
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):376-84. PubMed ID: 25066215
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.
Deviers A; Ken S; Filleron T; Rowland B; Laruelo A; Catalaa I; Lubrano V; Celsis P; Berry I; Mogicato G; Cohen-Jonathan Moyal E; Laprie A
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):385-93. PubMed ID: 25104068
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.
Saraswathy S; Crawford FW; Lamborn KR; Pirzkall A; Chang S; Cha S; Nelson SJ
J Neurooncol; 2009 Jan; 91(1):69-81. PubMed ID: 18810326
[TBL] [Abstract][Full Text] [Related]
10. ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy.
Ratai EM; Zhang Z; Fink J; Muzi M; Hanna L; Greco E; Richards T; Kim D; Andronesi OC; Mintz A; Kostakoglu L; Prah M; Ellingson B; Schmainda K; Sorensen G; Barboriak D; Mankoff D; Gerstner ER;
PLoS One; 2018; 13(6):e0198548. PubMed ID: 29902200
[TBL] [Abstract][Full Text] [Related]
11. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
Boonzaier NR; Larkin TJ; Matys T; van der Hoorn A; Yan JL; Price SJ
Radiology; 2017 Jul; 284(1):180-190. PubMed ID: 28240563
[TBL] [Abstract][Full Text] [Related]
12. Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma.
Raizer JJ; Koutcher JA; Abrey LE; Panageas KS; DeAngelis LM; Lis E; Xu S; Zakian KL
J Neurooncol; 2005 Jan; 71(2):173-80. PubMed ID: 15690135
[TBL] [Abstract][Full Text] [Related]
13. Quantification of serial changes in cerebral blood volume and metabolism in patients with recurrent glioblastoma undergoing antiangiogenic therapy.
Stadlbauer A; Pichler P; Karl M; Brandner S; Lerch C; Renner B; Heinz G
Eur J Radiol; 2015 Jun; 84(6):1128-36. PubMed ID: 25795194
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T
Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brainstem gliomas treated with radiotherapy.
Laprie A; Pirzkall A; Haas-Kogan DA; Cha S; Banerjee A; Le TP; Lu Y; Nelson S; McKnight TR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):20-31. PubMed ID: 15850898
[TBL] [Abstract][Full Text] [Related]
16. Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM.
Crawford FW; Khayal IS; McGue C; Saraswathy S; Pirzkall A; Cha S; Lamborn KR; Chang SM; Berger MS; Nelson SJ
J Neurooncol; 2009 Feb; 91(3):337-51. PubMed ID: 19009235
[TBL] [Abstract][Full Text] [Related]
17. Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas.
Server A; Kulle B; Gadmar ØB; Josefsen R; Kumar T; Nakstad PH
Eur J Radiol; 2011 Nov; 80(2):462-70. PubMed ID: 20708868
[TBL] [Abstract][Full Text] [Related]
18. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Kesari S; Ram Z;
CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638
[TBL] [Abstract][Full Text] [Related]
19. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
[TBL] [Abstract][Full Text] [Related]
20. NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma.
Gilbert MR; Pugh SL; Aldape K; Sorensen AG; Mikkelsen T; Penas-Prado M; Bokstein F; Kwok Y; Lee RJ; Mehta M
J Neurooncol; 2017 Jan; 131(1):193-199. PubMed ID: 27770279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
